Dignobroxol is a mucolytic agent produced in Germany by the pharmaceutical company Luitpold Pharma GmbH.
The international name of the drug is ambroxol. Also known under the trade names: Ambrobene, Ambrohexal, Ambroxol, Ambroxol-Vramed, Ambroxol-Hemofarm, Ambrolan, Ambrosan, Ambrosol, Deflegmin, Drops Bronhovern, Lazolvan, Medovent, Mucosolvan, Fervex for cough, Frenopect, Halixol.
Available in dosage form - an oral solution at a concentration of 7.5 mg/ml.
Indications for use: bronchitis, pneumonia, bronchial asthma, bronchiectasis, respiratory distress syndrome in premature babies and newborns - to improve sputum discharge.
Contraindicated in case of hypersensitivity, gastric ulcer and duodenal ulcer, in the first trimester of pregnancy, during breastfeeding.
Side effects: weakness, headache, stomach pain, nausea, vomiting, diarrhea, rash. With rapid intravenous administration, intense headaches and weakness are possible.
Interacts with antibiotics, increasing their concentration in sputum.
It is not recommended to combine it with antitussives that make it difficult to clear sputum.
The content of sorbitol and saccharin should be taken into account when used in patients with diabetes mellitus.